WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 599071
CAS#: 35991-93-6
Description: Nadoxolol HCl is a beta-adrenergic receptor blocker.
MedKoo Cat#: 599071
Name: Nadoxolol HCl
CAS#: 35991-93-6
Chemical Formula: C14H17ClN2O3
Exact Mass: 296.0928
Molecular Weight: 296.751
Elemental Analysis: C, 56.67; H, 5.77; Cl, 11.95; N, 9.44; O, 16.17
Synonym: Nadoxolol hydrochloride; Nadoxolol HCl; LL 1530; LL-1530; LL1530;
IUPAC/Chemical Name: (Z)-N',3-dihydroxy-4-(naphthalen-1-yloxy)butanimidamide hydrochloride
InChi Key: QMIHLTWUCXXBQQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H16N2O3.ClH/c15-14(16-18)8-11(17)9-19-13-7-3-5-10-4-1-2-6-12(10)13;/h1-7,11,17-18H,8-9H2,(H2,15,16);1H
SMILES Code: N/C(CC(O)COC1=C2C=CC=CC2=CC=C1)=N\O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
| Biological target: | Nadoxolol HCl is a beta-adrenergic receptor blocker. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
The following data is based on the product molecular weight 296.751 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Jaeger A, Kopferschmitt J, Sauder P, Benmatti A, Mantz JM. [Acute nadoxolol poisoning. A multicentric study of 35 cases]. Toxicol Eur Res. 1982 May;4(3):163-6. French. PubMed PMID: 7135390.
2: Bernard P, Bedane C, Catanzano G, Robbe J, Bonnetblanc JM. Acute generalized exanthematic pustulosis. An atypical case due to nadoxolol? Dermatologica. 1991;182(2):115-8. PubMed PMID: 1828772.
3: Misztal G, Gumieniczek A. Chromatographic analysis (TLC) aprindine and nadoxolol in human plasma. Acta Pol Pharm. 1994;51(3):215-8. PubMed PMID: 7872014.
4: Misztal G, Przyborowski L. Determination of nadoxolol in human plasma using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994 Oct 14;660(2):409-11. PubMed PMID: 7866535.
5: Jaeger A, Kopferschmitt J, Sauder P, Benmatti A, Mantz JM. [Acute poisoning caused by nadoxolol. Multi-center study of 35 cases]. Nouv Presse Med. 1982 Jun 12;11(28):2151-2. French. PubMed PMID: 7110977.
6: Mussini JM. [Peripheral neuropathy during treatment with nadoxolol]. Presse Med. 1985 Mar 30;14(13):748. French. PubMed PMID: 2986092.
7: Warembourg H, Ducloux G. [Clinical study of a new anti-arrhythmia agent: nadoxolol]. Lille Med. 1976 Apr;21(4 Suppl 2):386-8. French. PubMed PMID: 957857.
8: Kapoor M, Anand N, Koul S, Chimni SS, Manhas KS, Raina C, Parshad R, Taneja SC, Qazi GN. Kinetic resolution of 1-chloro-3-(1-naphthyloxy)-2-propanol, an intermediate in the synthesis of beta-adrenergic receptor blockers. Bioorg Chem. 2003 Jun;31(3):259-69. PubMed PMID: 12818235.
